All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Advantages and limitations of 3D organoids and ex vivo tumor tissue culture in personalized medicine for prostate cancer

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F22%3A10157765" target="_blank" >RIV/00098892:_____/22:10157765 - isvavai.cz</a>

  • Alternative codes found

    RIV/61989592:15110/22:73614939

  • Result on the web

    <a href="https://www.linkos.cz/english-summary/klinicka-onkologie-journal/2022-12-15-6-en/vyhody-a-omezeni-3d-organoidu-a-ex-vivo-kultivace-nadorovych-tkani-v-personalizo-1/" target="_blank" >https://www.linkos.cz/english-summary/klinicka-onkologie-journal/2022-12-15-6-en/vyhody-a-omezeni-3d-organoidu-a-ex-vivo-kultivace-nadorovych-tkani-v-personalizo-1/</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.48095/ccko2022473" target="_blank" >10.48095/ccko2022473</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Advantages and limitations of 3D organoids and ex vivo tumor tissue culture in personalized medicine for prostate cancer

  • Original language description

    Background: Current in vitro model systems do not fully reflect the biological and clinical diversity of prostate cancer (PCa). Organoids are 3D in vitro cell cultures that may better recapitulate disease heterogeneity and retain parental tumor characteristics. Short-term ex vivo culture of PCa tissues may also facilitate drug testing in personalized medicine. Materials and methods: For organoid culture, we have processed both cancer and normal tissues from 50 patients who underwent radical prostatectomy or transurethral resection of the prostate. In addition, we exploited the ex vivo tissue culture technique and performed short-term chemotherapy assay using gemcitabine and Chk1 inhibitor MU380 in 10 patient samples. Results: In total, we were able to cultivate organoids from 58% of tumors (29/50) and 69% of normal tissue (20/29). Immunohistochemical staining of two representative cases revealed cell positivity for pan-cytokeratin confirming the presence of epithelial cells. However, the overexpression of AMACR and ERG proteins in tumors was not recapitulated in organoids. Another limitation was the propagation of organoids only up to 3 weeks till the first passage. Next, a short-term drug test was performed for ten patients using ex vivo tissue culture. Samples from prostatectomies mostly presented a low proliferation rate as assessed by Ki-67 staining. Another drawback of this approach was inconsistent tissue morphology among particular tissue fragments. Only one case showed a high proliferation rate for drug testing and tumor tissue was present in all tested samples. In our work, we also provide an overview of recent studies and a detailed comparison of culture conditions. Conclusion: We have established cultures of both organoids and tissue fragments from PCa patient samples. However, the expression of tumor markers was not recapitulated in organoids. Inconsistent morphology among tissue fragments and low proliferation hampered the interpretation of the drug testing in most cases. Still, these approaches may be promising using tissues from metastatic castration-resistant prostate cancer.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database

  • CEP classification

  • OECD FORD branch

    30109 - Pathology

Result continuities

  • Project

    Result was created during the realization of more than one project. More information in the Projects tab.

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2022

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Klinická onkologie

  • ISSN

    0862-495X

  • e-ISSN

    1802-5307

  • Volume of the periodical

    35

  • Issue of the periodical within the volume

    6

  • Country of publishing house

    CZ - CZECH REPUBLIC

  • Number of pages

    9

  • Pages from-to

    473-481

  • UT code for WoS article

  • EID of the result in the Scopus database

    2-s2.0-85143963304